Sabine Lauer

11 years' follow-up of trastuzumab after adjuvant chemotherapy in HER2-positive early breast cancer: final analysis of the HERceptin Adjuvant (HERA) trial

David Cameron, Martine Piccart, Richard D. Gelber et al. · The Lancet · 2017 · 1K citations · Full text

Medicine, Immunology, Oncology +17

Role of Troponins I and T and <i>N</i>-Terminal Prohormone of Brain Natriuretic Peptide in Monitoring Cardiac Safety of Patients With Early-Stage Human Epidermal Growth Factor Receptor 2–Positive Breast Cancer Receiving Trastuzumab: A Herceptin Adjuvant Study Cardiac Marker Substudy

Dimitrios Zardavas, Thomas Suter, Dirk J. van Veldhuisen et al. · Journal of Clinical Oncology · 2017 · 165 citations

Medicine, Cardiology, Oncology +17

Safety and tolerability of subcutaneous trastuzumab for the adjuvant treatment of human epidermal growth factor receptor 2-positive early breast cancer: SafeHer phase III study's primary analysis of 2573 patients

Joseph Gligorov, Beyhan Ataseven, Mark Verrill et al. · European Journal of Cancer · 2017 · 46 citations · Full text

Medicine, Oncology, Pharmacology +17

A Statistical Framework for Hypothesis Testing in Real Data Comparison Studies

Anne‐Laure Boulesteix, Robert Hable, Sabine Lauer et al. · The American Statistician · 2015 · 38 citations · Full text

Natural Sciences, Bioinformatics, Biostatistics +14

A real-world study of cardiac events in &gt; 3700 patients with HER2-positive early breast cancer treated with trastuzumab: final analysis of the OHERA study

Elisabet Lidbrink, Ewa Chmielowska, Burkhard Otremba et al. · Breast Cancer Research and Treatment · 2018 · 36 citations · Full text

Medicine, Cardiology, Oncology +17